Krishna Chaitanya Chava

“Coming to the small molecule CDMO, the business has continued to deliver robust operation execution in Q2, reporting an 86% growth with the sales of 875 crores.”

“Within the CDMO side, the division has continued to deliver strong operation execution in Q1, reporting a growth of 69% with the sales of 835 crores on the small molecule side.”

“The CDMO business delivered robust operational execution for the full year, clocking at a little over 2,000 crores at 2,080 crores. For the small molecule CDMO, we have clocked a growth of about 38% with the sales for the full year at 1896 crores.”